{"id":"NCT00321620","sponsor":"Amgen","briefTitle":"Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer","officialTitle":"A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-04-01","primaryCompletion":"2009-10-01","completion":"2012-02-24","firstPosted":"2006-05-04","resultsPosted":"2014-03-21","lastUpdate":"2018-08-29"},"enrollment":1904,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Bone Metastases"],"interventions":[{"type":"DRUG","name":"zoledronic acid","otherNames":["Zometa"]},{"type":"BIOLOGICAL","name":"denosumab","otherNames":[]}],"arms":[{"label":"zoledronic acid","type":"ACTIVE_COMPARATOR"},{"label":"denosumab","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases in men with hormone-refractory prostate cancer","primaryOutcome":{"measure":"Time to the First On-Study SRE (Non-inferiority)","timeFrame":"Up to 40.5 months","effectByArm":[{"arm":"Zoledronic Acid","deltaMin":521,"sd":null},{"arm":"Denosumab","deltaMin":629,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0002"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["21353695","25425475","25449207","33270906","26335402","26093811","24722180","23975226","22975218"],"seeAlso":["http://download.veritasmedicine.com/REGFILES/amgen/Amgen_results_disclaimer.pdf","http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":568,"n":945},"commonTop":["Anaemia","Back pain","Decreased appetite","Nausea","Constipation"]}}